Lung Cancer

Web Exclusives | July 28, 2021
Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations.
Web Exclusives | July 28, 2021
A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.
Web Exclusives | July 28, 2021
Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRASG12C-mutated NSCLC subtypes.
Web Exclusives | July 28, 2021
Results from an incidental lung nodule program implemented in a community healthcare system demonstrates this program detects lung cancer in patients who are otherwise ineligible for LDCT screening.
Web Exclusives | June 23, 2021
Patients with advanced KRASG12C harboring NSCLC maintained quality of life and physical functioning with tolerable side effects while being treated with sotorasib.
Web Exclusives | June 23, 2021
Data indicate a steady improvement over the past decade in NSCLC survival rates due to immunotherapy and targeted therapy.
Web Exclusives | June 23, 2021
A recent review article provided best practices for biomarker testing and recommendations for the diagnosis and management of patients with advanced NSCLC.
Web Exclusives | June 23, 2021
Treatment timing and type at time of diagnosis of stage III NSCLC influences patients’ overall survival, with gender and race differences also influencing therapy.
Web Exclusives | June 23, 2021
Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant accelerated approval for sotorasib for patients with KRASG12C-mutated NSCLC.
Web Exclusives | May 27, 2021
The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.
Page 1 of 12
Results 1 - 10 of 115

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code